About Patrick Lu

Dr. Patrick Y. Lu founded and has led Sirnaomics from an early discovery startup to a siRNA therapeutics product company, with multiple programs currently at the clinical stage. Dr. Lu brings 25+ years of nucleic acid drug development experience at Novartis, Digene, and Intradigm, where he was a co-founder. He has helped Sirnaomics raising over $270 million and develop the novel siRNA therapeutic, STP705, for the treatment of cancer and fibrosis diseases.